There’s a lot to be learned from the COVID-19 pandemic, including how we can be better prepared for future pandemics.
The ideal pandemic response must include a pharmaceutical approach, both vaccines to prevent new infections and treatments to address those infected.
This presentation will discuss how new siRNA and mRNA modalities could be deployed as treatments and as vaccines respectively, and the potential advantages they could offer to traditional approaches. The ongoing efforts to develop these therapies for COVID-19 will be discussed as well as the presently existing hurdles. If COVID-19 has come too early for these platforms to reach their infectious disease-fighting potential, then it should serve as the start of the development process, not the end.
The ideal characteristics of a pharmaceutical response to a pandemic:
- Rapid development time
- Rapid deployment time
- Efficacy, but not at the expense of safety
- Specificity, but not at the expense of flexibility
It is possible that new modalities will meet these characteristics better than established vaccines. Watch the webinar to learn how.